On January 10, 2024, ViiV Healthcare, in collaboration with Pfizer and Shionogi, submitted a new drug application to Health Canada for cabotegravir long-acting injectable and tablets for pre-exposure prophylaxis (PrEP). This submission is currently undergoing priority review. Cabotegravir, when used in combination with safer sex practices, aims to reduce the risk of sexually acquired HIV. If approved, this therapy will mark a significant milestone as the first long-acting treatment option for HIV PrEP, providing a novel approach to HIV prevention.
In other regulatory news, the European Commission has granted authorization for Apretude, which includes cabotegravir long-acting injectable and tablets, for HIV prevention. Additionally, the US Food and Drug Administration (FDA) has granted Priority Review status to ViiV Healthcare’s New Drug Application for cabotegravir long-acting as a preventive measure against HIV. The FDA’s Priority Review designation is reserved for drugs that demonstrate substantial improvements in treatment.
Furthermore, the FDA has recognized the breakthrough potential of long-acting, injectable cabotegravir for HIV PrEP by granting it Breakthrough Therapy Designation. This designation is based on the encouraging efficacy and safety results obtained from the HPTN 083 clinical trial. This trial, a phase IIb/III randomized, multicenter, double-blind study, compared the effectiveness of long-acting, injectable cabotegravir with daily oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in preventing HIV transmission among men who have sex with men and transgender women who have sex with men.
For further information regarding the specific drug submission to Health Canada, direct inquiries can be made to ViiV Healthcare through their media contacts.
[bs_slider_forecast ticker=”GSK
“]
GlaxoSmithKline (GSK) Stock Shows Positive Performance and Potential for Growth
On January 10, 2024, GlaxoSmithKline (GSK) stock exhibited positive performance. The stock was trading near the top of its 52-week range and above its 200-day simple moving average. The price of GSK shares increased by $0.22 since the market last closed, representing a rise of 0.55%. GSK stock opened at $39.87, which was $0.11 higher than its previous close. The fact that GSK is trading near the top of its 52-week range and above its 200-day simple moving average is a positive sign for investors. It indicates that the stock has been performing well over the past year and has the potential for further growth. Moreover, the stock being above its 200-day simple moving average is another positive indicator. Investors may attribute the positive performance of GSK stock to various factors, but it is important to note that stock prices can be influenced by numerous factors. Therefore, it is advisable for investors to conduct thorough research and analysis before making any investment decisions.
[stock_market_widget type=”chart” template=”basic” color=”#3946CE” assets=”GSK
” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” api=”yf”]
GlaxoSmithKline (GSK) Stock Performance: Mixed Results in Total Revenue, Net Income, and EPS – Factors to Consider for Investors
On January 10, 2024, GlaxoSmithKline (GSK) stock experienced mixed performance, reflecting the company’s recent financial results. GSK reported total revenue of $36.12 billion for the past year, a decrease of 23.01% compared to the previous year. However, the total revenue for the most recent quarter saw a 14.73% increase, reaching $10.31 billion. In terms of net income, GSK reported $18.42 billion for the past year, a significant increase of 205.48% compared to the previous year. However, the net income for the most recent quarter was $1.85 billion, indicating a decrease of 8.87% compared to the previous quarter. The earnings per share (EPS) for the past year was $9.02, a remarkable increase of 203.08% compared to the previous year. However, the EPS for the most recent quarter was $0.91, representing a decrease of 8.91% compared to the previous quarter. The mixed performance of GSK stock on this particular day can be attributed to the contrasting figures in total revenue, net income, and EPS. Investors should consider various factors beyond just financial figures when evaluating a company’s stock performance. Factors such as industry trends, competition, regulatory environment, and pipeline of new products can significantly impact a company’s long-term prospects. Stock performance is subject to market volatility and can fluctuate based on various factors. Therefore, investors should conduct thorough research and consult with financial advisors before making any investment decisions.
